SUNNYVALE, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

Silk Road Medical’s management is scheduled to present on Tuesday, January 12, 2021 at 11:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/

Read More: ​​https://www.globenewswire.com/news-release/2020/12/17/2147400/0/en/Silk-Road-Medical-to-Present-at-the-39th-Annual-J-P-Morgan-Healthcare-Conference.html

Digital health company Omada Health presented encouraging research results on Tuesday suggesting its diabetes prevention platform — which virtually connects prediabetic patients with health coaches and clinicians — could help curb the symptoms of the disease as well as an equivalent program delivered in person.

The research is in some ways the biggest test yet of a digitally rendered diabetes treatment program ever performed. The study — a randomized controlled trial of nearly 600 people with prediabetes — is larger, longer, and more rigorous than previous studies of similar programs. Omada shared its findings in a presentation during ObesityWeek, a virtual medical conference organized by the Obesity Society; they have yet to be published in a scientific journal.

​Read More: ​https://www.statnews.com/2020/11/03/omada-health-prediabetes-predict-study/

SUNNYVALE, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to the company’s Board of Directors. Simultaneously, the company also announced the resignation of current board member, Ruoxi Chen. Both of these changes are effective immediately.

Ballinger, the recently appointed Chief Executive Officer of Aldevron, brings decades of experience in the medical device industry. Prior to joining Aldevron, he spent 25 years at Boston Scientific, a company focused on a variety of interventional medical specialties. During his last nine years at Boston Scientific, he served as Executive Vice President and Global President of the Interventional Cardiology division. Under his leadership, Ballinger grew the division to a $3 billion global business. Ballinger earned his BS in Mechanical Engineering from Michigan Technological University, and his MBA from the University of Minnesota’s Carlson School of Management.

​Read More: ​https://www.globenewswire.com/news-release/2020/12/03/2139512/0/en/Silk-Road-Medical-Announces-Changes-to-Board-of-Directors.html